Daniela G.
- Country
- Germany
- Department
- Klinik für Dermatologie und Allergologie
Research Overview
- Comparative Study of JPB898 and Nivolumab in Combination with Ipilimumab for Advanced Unresectable/Metastatic Melanoma
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase 3 Evaluation of Fianlimab and Cemiplimab Versus Pembrolizumab in Treatment-Naïve Unresectable Locally Advanced or Metastatic Melanoma
Data & Insights
Has run more than one trial at 84 of 222 partner sites.
Specializations
Melanoma Research
The investigator specializes in advanced research involving cutaneous melanoma treatment approaches, with particular focus on various disease stages from II to IV.
- Stage II High-Risk Melanoma Management
- Advanced Unresectable Melanoma
- Metastatic Melanoma Treatment
The investigator explores innovative therapeutic strategies for both early-stage and advanced melanoma cases.
Immunotherapy Applications
Focuses on investigating novel immunotherapeutic approaches using various therapeutic antibodies and their combinations.
- Combination Immunotherapy Protocols
- Adjuvant Treatment Strategies
- Novel Antibody Therapeutics
Evaluates both established and emerging immunotherapy agents for melanoma treatment.
Treatment Innovation
Leads research in perioperative therapy and explores various drug administration methods for melanoma treatment.
- Subcutaneous Drug Administration
- Biomarker-Based Stratification
- Comparative Treatment Efficacy
Investigates innovative therapeutic approaches for improving patient outcomes in melanoma treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.